Related Experiment Video

Updated: Apr 7, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K

In Silico Interaction and Docking Studies Indicate a New Mechanism for PML Dysfunction in Gastric Cancer and Suggest

Zeinab Imani-Saber1, Soudeh Ghafouri-Fard

  • 1Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Asian Pacific Journal of Cancer Prevention : APJCP
|July 12, 2015
PubMed

Insights

Helicobacter pylori CagA protein may degrade the promyelocytic leukemia (PML) tumor suppressor in gastric cancer. Imatinib kinase inhibitor treatment can restore PML function, suggesting a new therapeutic strategy for H. pylori-associated gastric cancer.

Area of Science:

  • Oncology
  • Microbiology
  • Molecular Biology

Background:

  • Gastric cancer is a prevalent malignancy with multiple risk factors, including Helicobacter pylori (H. pylori) infection.
  • Loss of the promyelocytic leukemia (PML) tumor suppressor gene is observed in gastric cancer, though mutations are absent.
  • The H. pylori CagA protein is known to regulate tumor suppressor genes post-transcriptionally.

Purpose of the Study:

  • To investigate the potential interaction between PML and CagA proteins using in silico analyses.
  • To explore the mechanism of PML degradation in gastric cancer.
  • To identify potential therapeutic interventions targeting this pathway.

Main Methods:

  • In silico analyses including protein-protein interaction and docking studies were performed.
  • Computational methods were used to assess the stability of PML-CagA interactions.
  • The effect of imatinib, a kinase inhibitor, on PML function was evaluated.

Main Results:

  • In silico studies indicated a stable interaction between PML and CagA proteins.
  • The CagA protein may contribute to PML degradation in gastric cancer.
  • Imatinib was shown to restore PML function by inhibiting casein kinase 2.

Conclusions:

  • A potential mechanism for PML degradation in gastric cancer involves interaction with H. pylori CagA protein.
  • Imatinib kinase inhibitor shows promise in restoring PML tumor suppressor function.
  • These findings suggest a novel therapeutic approach for H. pylori-related gastric cancer.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
765